Navigation Links
Jazz Pharmaceuticals Announces Third Quarter 2011 Financial Results
Date:11/1/2011

PALO ALTO, Calif., Nov. 1, 2011 /PRNewswire/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the third quarter of 2011.

Total revenues for the quarter ended September 30, 2011 were $73.3 million, compared to $44.8 million for the third quarter of 2010.  Total revenues include net product sales, royalties and contract revenues.

Adjusted net income for the third quarter of 2011 was $44.3 million, or $0.94 per diluted share, compared to $17.2 million, or $0.41 per diluted share, for the third quarter of 2010.  A reconciliation of GAAP net income to adjusted net income and the related per diluted share amounts is included with this press release.

GAAP net income for the third quarter of 2011 was $32.5 million, or $0.69 per diluted share, compared to a GAAP net income of $13.2 million, or $0.32 per diluted share, for the third quarter of 2010.  The company's GAAP net income in the third quarter of 2011 included costs of $6.0 million associated with the proposed transaction with Azur Pharma Public Limited Company (formerly Azur Pharma Limited) announced in September and a loss on extinguishment of debt of approximately $1.1 million associated with prepayment of a term loan in July 2011.

Net sales of Xyrem® (sodium oxybate) increased significantly to $62.5 million for the third quarter of 2011, compared to net sales of $37.2 million for the third quarter of 2010.  Net sales of once-daily Luvox CR® (fluvoxamine maleate) were $9.7 million for the third quarter of 2011, compared to $6.6 million for the prior year period.

"This strong quarter reflects the continued success of Xyrem as an important medical therapy for patients experiencing the two key symptoms of narcolepsy," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.  "In the quarter, we also took a significant step forward towards strengthening our platform for growth and diversifying our product portfolio by entering into an agreement to combine with Azur Pharma.  We continue to expect the transaction to close in the first quarter of 2012."

Selling, general and administrative expenses and research and development expenses combined for the third quarter of 2011 were $33.8 million, compared to $25.4 million for the third quarter of 2010, reflecting higher legal and professional services expenses, primarily related to the Azur Pharma transaction, higher headcount related expenses, including stock-based compensation expense, and lower product development spending.  

During the quarter, the company prepaid the entire remaining balance, or $33.3 million, of its long-term debt.  Cash and marketable securities as of September 30, 2011 were $113 million.  

2011 Financial Guidance Jazz Pharmaceuticals is providing updated full year 2011 financial guidance as follows:


  • Total product sales
  • Xyrem
  • Luvox CR
  • $ 261 - 268 million

    $ 230 - 235 million

    $   31 -   33 million


  • SG&A and R&D combined expenses
  • $ 114 - 118 million*


  • GAAP net income per diluted share
  • $ 2.76 - 2.81


  • Adjusted net income per diluted share
  • $ 3.45 - 3.50 *  Includes estimated expenses associated with the Azur Pharma transaction.A reconciliation of GAAP net income to adjusted net income and the related per diluted share amounts is included with this press release.

    Conference Call DetailsJazz Pharmaceuticals will host an investor conference call and live audio webcast today at 1:30 p.m. PT/4:30 p.m. ET to provide a business update and to discuss 2011 third quarter results and updated 2011 financial guidance.  The live webcast may be accessed from the Investors section of the company's website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary.  Investors may participate in the conference call by dialing 866-700-7173 in the U.S., or 617-213-8838 outside the U.S., and entering passcode 78394935.

    An archived version of the webcast will be available for at least one week on the investors section of the Jazz Pharmaceuticals' website at www.jazzpharmaceuticals.com.

    About Jazz Pharmaceuticals, Inc.Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.  For further information see www.jazzpharmaceuticals.com.

    Non-GAAP Financial Measures To supplement our financial results and financial guidance presented on a GAAP basis, we use the non-GAAP measures adjusted net income and adjusted net income per diluted share.  We believe these non-GAAP financial measures are helpful in understanding our past financial performance and our potential future results.  They are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with our consolidated financial statements prepared in accordance with GAAP.  Our management regularly uses these supplemental non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions.  Compensation of our employees is based in part on the performance of our business based on these non-GAAP measures.  In addition, we believe that the use of these non-GAAP measures enhances the ability of investors to compare our results from period to period.  Investors should note that adjusted net income and adjusted net income per diluted share, as used by Jazz Pharmaceuticals, may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by our competitors and other companies.  Adjusted net income and adjusted net income per diluted share exclude from the comparable GAAP measures:  revenue related to upfront and milestone payments, amortization of intangible assets, stock-based compensation, non-cash interest expense associated with a debt discount and debt issuance costs, loss on extinguishment of debt and costs associated with the proposed transaction with Azur Pharma.

    "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' growth potential and future financial performance, including 2011 financial guidance, and statements related to the anticipated consummation of the business combination transaction between Jazz Pharmaceuticals and Azur Pharma and the timing thereof.  These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties.  Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: Jazz Pharmaceuticals' dependence on sales of Xyrem and its ability to increase sales of its Xyrem and Luvox CR products; competition, including potential generic competition; Jazz Pharmaceuticals' dependence on single source suppliers and manufacturers; the ability of Jazz Pharmaceuticals to protect its intellectual property and defend its patents; regulatory obligations and oversight; Jazz Pharmaceuticals' cash flow; Jazz Pharmaceuticals' ability to complete the transaction with Azur Pharma on the proposed terms and schedule; and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission (SEC) filings and reports, including in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 and preliminary proxy statement related to the Azur Pharma transaction, in each case filed with the SEC.  Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

    Additional Information and Where to Find ItIn connection with the proposed transaction, Jazz Pharmaceuticals and Azur Pharma have filed documents with the SEC, including the filing by Jazz Pharmaceuticals of a preliminary proxy statement relating to the proposed transaction and the filing by Azur Pharma of a registration statement on Form S-4 that includes the joint proxy statement/prospectus relating to the proposed transaction.  After the registration statement has been declared effective by the SEC, a definitive joint proxy statement/prospectus will be filed with the SEC by Jazz Pharmaceuticals and Azur Pharma and mailed to Jazz Pharmaceuticals' stockholders in connection with the proposed transaction.  INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM S-4 AND THE RELATED PRELIMINARY PROXY STATEMENT/PROSPECTUS AND, WHEN IT BECOMES AVAILABLE, THE DEFINITIVE PROXY STATEMENT/PROSPECTUS BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, AZUR AND THE PROPOSED TRANSACTION.  Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC's web site at www.sec.gov, by directing a request to Jazz Pharmaceuticals' Investor Relations department at Jazz Pharmaceuticals, Inc., Attention: Investor Relations, 3180 Porter Drive, Palo Alto, California 94304, or to Jazz Pharmaceuticals' Investor Relations department at 650-496-2800 or by email to investorinfo@jazzpharma.com.  Investors and security holders may obtain free copies of the documents filed with the SEC on Jazz Pharmaceuticals' website at www.jazzpharmaceuticals.com under the heading "Investors" and then under the heading "SEC Filings."

    Jazz Pharmaceuticals and its directors and executive officers and Azur Pharma and its directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of Jazz Pharmaceuticals in connection with the proposed transaction.  Information regarding the special interests of these directors and executive officers in the proposed transaction is included in the proxy statement/prospectus described above.  Additional information regarding the directors and executive officers of Jazz Pharmaceuticals is also included in Jazz Pharmaceuticals' proxy statement for its 2011 Annual Meeting of Stockholders, which was filed with the SEC on April 12, 2011.  These documents are available free of charge at the SEC's web site at www.sec.gov and from Investor Relations at Jazz Pharmaceuticals as described above.  

    This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

    JAZZ PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share amounts) (Unaudited) Three Months Ended
    September 30,Nine Months Ended
    September 30,2011201020112010 Revenues: Product sales, net

    $
    72,216$
    43,838$ 185,583$ 117,649 Royalties

    7926302,3041,909 Contract revenues

    285285854854 Total revenues

    73,29344,753188,741120,412 Operating expenses: Cost of product sales

    3,9013,09110,0808,775 Selling, general and administrative

    30,54718,04072,55251,926 Research and development

    3,2797,31710,35621,494 Intangible asset amortization

    1,8621,8625,5865,963 Total operating expenses

    39,58930,31098,57488,158 Income from operations

    33,70414,44390,16732,254 Interest income and other, net

    4(3)63 Interest expense

    (129)(1,197)(1,565)(11,651) Loss on extinguishment of debt

    (1,097)-(1,097)(12,287) Net income  

    $
    32,482$
    3,243$   87,511$
    8,319 Net income per share: Basic

    $
    .77$
    .34$
    2.12$
    .24 Diluted

    $
    .69$
    .32$
    .88$
    .22 Weighted-average common shares used in computing   net income per share: Basic

    42,02838,96541,20635,294 Diluted

    47,24141,73746,57738,233 JAZZ PHARMACEUTICALS, INC. SUMMARY OF PRODUCT SALES, NET (In thousands) (Unaudited) Three Months Ended
    September 30,Nine Months Ended
    September 30,2011201020112010Xyrem

    $
    2,547$
    37,231$ 161,503$   99,699Luvox CR

    9,6696,60724,08017,950Total

    $
    72,216$
    43,838$ 185,583$ 117,649JAZZ PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands) (Unaudited) September 30,December 31,20112010ASSETSCurrent assets:Cash and cash equivalents

    $
    ,215$
    44,794Marketable securities

    12,133-Restricted cash

    -400Accounts receivable, net of allowances

    31,42822,081Inventories

    4,2975,046Prepaid expenses

    2,5351,858Other current assets

    532279Total current assets

    152,14074,458Property and equipment, net

    930690Intangible assets, net

    16,44722,033Goodwill

    38,21338,213Other long-term assets

    83335Total assets

    $
    207,813$
    35,729LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:Accounts payable

    $
    8,463$
    3,049Accrued liabilities

    35,83423,572Purchased product rights liability

    4,8754,500Liability under government settlement

    7,2254,128Revolving credit facility

    -7,350Current portion of long-term debt

    -16,064Deferred revenue

    1,1381,273Total current liabilities

    57,53559,936Purchased product rights liability, non-current

    7504,500Liability under government settlement, non-current

    -6,978Long-term debt, less current portion

    -24,629Deferred rent

    -82Deferred revenue, non-current

    8,1999,053Total stockholders' equity

    141,32930,551Total liabilities and stockholders' equity

    $
    207,813$
    35,729 JAZZ PHARMACEUTICALS, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (In thousands, except per share amounts) (Unaudited) Three Months Ended

    September 30,Nine Months Ended
    September 30,2011201020112010 GAAP net income  

    $
    32,482$
    3,243$   87,511$
    8,319 Add: Intangible asset amortization

    1,8621,8625,5865,963 Stock-based compensation expense

    3,1952,1779,7585,969 Non-cash interest expense

    -2523942,175 Loss on extinguishment of debt

    1,097-1,09712,287 Azur Pharma transaction related costs

    5,974-5,974- Deduct: Contract revenues

    (285)(285)(854)(854) Adjusted net income  

    $
    44,325$
    7,249$ 109,466$   33,859 GAAP net income per diluted share

    $
    .69$
    .32$
    .88$
    .22 Adjusted net income per diluted share

    $
    .94$
    .41$
    2.35$
    .89 Shares used in computing GAAP and adjusted net income per diluted share amounts

    47,24141,73746,57738,233 JAZZ PHARMACEUTICALS, INC. RECONCILIATION OF GAAP TO NON-GAAP 2011 FINANCIAL GUIDANCE (In millions, except per share amounts) GAAP net income $128-131 Add: Intangible asset amortization 7 Stock-based compensation expense 13 Non-cash interest expense and loss on extinguishment of debt 2 Azur Pharma transaction related costs 10-11 Deduct: Contract revenues (1) Adjusted net income $160-163 GAAP net income per diluted share $2.76-2.81 Adjusted net income per diluted share $3.45-3.50 Shares used in computing GAAP and adjusted net income per diluted share amounts 46-47
    '/>"/>

    SOURCE Jazz Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Back-Up Compounds and S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
    2. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
    3. Rock Creek Pharmaceuticals Announces Completion of Medical Conferences on Anatablocâ„¢ Research, Comments on Research Presentation at American Thyroid Association Annual Meeting
    4. Avanir Pharmaceuticals Submits European Marketing Authorization Application for NUEDEXTA
    5. Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results
    6. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
    7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results on November 3, 2011
    8. Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance
    9. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Expansion of Oncology Programs for Its Clients
    10. Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals
    11. Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - October 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
    (Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
    (Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
    Breaking Medicine Technology:
    (Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
    (Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
    (Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
    (Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
    Breaking Medicine News(10 mins):